192 related articles for article (PubMed ID: 16086592)
1. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers.
Bhatia A; Schäfer HJ; Hrycyna CA
Biochemistry; 2005 Aug; 44(32):10893-904. PubMed ID: 16086592
[TBL] [Abstract][Full Text] [Related]
2. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
Henriksen U; Gether U; Litman T
J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
[TBL] [Abstract][Full Text] [Related]
3. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
[TBL] [Abstract][Full Text] [Related]
4. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
Henriksen U; Fog JU; Litman T; Gether U
J Biol Chem; 2005 Nov; 280(44):36926-34. PubMed ID: 16107343
[TBL] [Abstract][Full Text] [Related]
5. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
Diop NK; Hrycyna CA
Biochemistry; 2005 Apr; 44(14):5420-9. PubMed ID: 15807535
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
7. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
Xu J; Peng H; Chen Q; Liu Y; Dong Z; Zhang JT
Cancer Res; 2007 May; 67(9):4373-81. PubMed ID: 17483351
[TBL] [Abstract][Full Text] [Related]
8. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system.
Wakabayashi K; Nakagawa H; Adachi T; Kii I; Kobatake E; Kudo A; Ishikawa T
J Exp Ther Oncol; 2006; 5(3):205-22. PubMed ID: 16528971
[TBL] [Abstract][Full Text] [Related]
9. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
Ejendal KF; Diop NK; Schweiger LC; Hrycyna CA
Protein Sci; 2006 Jul; 15(7):1597-607. PubMed ID: 16815914
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
Ejendal KF; Hrycyna CA
Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
[TBL] [Abstract][Full Text] [Related]
11. Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter.
Orbán TI; Seres L; Ozvegy-Laczka C; Elkind NB; Sarkadi B; Homolya L
Biochem Biophys Res Commun; 2008 Mar; 367(3):667-73. PubMed ID: 18182157
[TBL] [Abstract][Full Text] [Related]
12. Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.
Ozvegy-Laczka C; Laczkó R; Hegedus C; Litman T; Várady G; Goda K; Hegedus T; Dokholyan NV; Sorrentino BP; Váradi A; Sarkadi B
J Biol Chem; 2008 Sep; 283(38):26059-70. PubMed ID: 18644784
[TBL] [Abstract][Full Text] [Related]
13. The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
Macalou S; Robey RW; Jabor Gozzi G; Shukla S; Grosjean I; Hegedus T; Ambudkar SV; Bates SE; Di Pietro A
Cell Mol Life Sci; 2016 May; 73(9):1927-37. PubMed ID: 26708291
[TBL] [Abstract][Full Text] [Related]
14. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.
Ozvegy C; Váradi A; Sarkadi B
J Biol Chem; 2002 Dec; 277(50):47980-90. PubMed ID: 12374800
[TBL] [Abstract][Full Text] [Related]
15. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.
Telbisz Á; Özvegy-Laczka C; Hegedűs T; Váradi A; Sarkadi B
Biochem J; 2013 Mar; 450(2):387-95. PubMed ID: 23205634
[TBL] [Abstract][Full Text] [Related]
16. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
17. Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.
Polgar O; Ozvegy-Laczka C; Robey RW; Morisaki K; Okada M; Tamaki A; Koblos G; Elkind NB; Ward Y; Dean M; Sarkadi B; Bates SE
Biochemistry; 2006 Apr; 45(16):5251-60. PubMed ID: 16618113
[TBL] [Abstract][Full Text] [Related]
18. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.
Xu J; Liu Y; Yang Y; Bates S; Zhang JT
J Biol Chem; 2004 May; 279(19):19781-9. PubMed ID: 15001581
[TBL] [Abstract][Full Text] [Related]
19. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2.
Liu Y; Yang Y; Qi J; Peng H; Zhang JT
J Pharmacol Exp Ther; 2008 Jul; 326(1):33-40. PubMed ID: 18430864
[TBL] [Abstract][Full Text] [Related]
20. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
Li YF; Polgar O; Okada M; Esser L; Bates SE; Xia D
J Mol Graph Model; 2007 Mar; 25(6):837-51. PubMed ID: 17027309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
